Physician profile

Nicholas Pappas

Cardiovascular Disease · Metairie, LA

NPI 1912079120

$2,944.50

in general payments reported to CMS, 2019-2025

22 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Novartis Pharmaceuticals Corporation $434.50 2019-2021
Pfizer INC. $392.60 2019-2022
Janssen Pharmaceuticals, INC $352.01 2019-2021
Sanofi-Aventis U.S. LLC $262.87 2019-2021
E.R. Squibb & Sons, L.L.C. $202.79 2019-2020
Amgen INC. $202.72 2019-2021
Abiomed $150.46 2019
Amarin Pharma, INC. $147.68 2019-2021
Regeneron Healthcare Solutions, INC. $125.96 2019-2021
Boehringer Ingelheim Pharmaceuticals, INC. $120.97 2019-2020
Astrazeneca Pharmaceuticals LP $95.62 2019-2020
Zoll Services LLC (A/K/A Zoll Lifecor Corp) $84.41 2019
Actelion Pharmaceuticals US, INC. $74.38 2019-2021
Gilead Sciences, INC. $68.17 2019
Esperion Therapeutics, INC. $55.20 2021
Show all 22 companies
CompanyGeneral paymentsYearsTop products
Bayer Healthcare Pharmaceuticals INC. $49.29 2021
Otsuka America Pharmaceutical, INC. $33.81 2019
Terumo Medical Corporation $31.41 2019
Genzyme Corporation $18.74 2022
United Therapeutics Corporation $13.97 2019
Medtronic Vascular, INC. $13.83 2019
Arbor Pharmaceuticals, INC. $13.11 2019

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Nicholas Pappas

$2,944.50

in general payments reported 2019-2025

Years
2019-2022
Top company
Novartis Pharmaceuticals Corporation

https://glasscript.com/doctor/222916/nicholas-pappas

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.